Premium
Expression of the proliferation marker K i‐67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas
Author(s) -
Müssig Karsten,
Wehrmann Tobias,
Dittmann Helmut,
Wehrmann Manfred,
Ueberberg Bianca,
Schulz Stefan,
Bares Roland,
Petersenn Stephan
Publication year - 2012
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2012.04343.x
Subject(s) - immunohistochemistry , medicine , thyroid carcinoma , thyroid cancer , proliferation marker , progesterone receptor , thyroid , pathology , histology , ki 67 , receptor , endocrinology , gastroenterology , cancer , breast cancer , estrogen receptor
Summary Objective Although the prognosis of differentiated thyroid carcinoma ( DTC ) is excellent, with 10‐year survival rates of about 90%, about one‐third of patients experiences recurrent disease. We aimed to identify novel histological prognostic factors to optimize treatment and follow‐up of patients at risks. Design Retrospective analysis of patients diagnosed from J anuary 1990 to M arch 2004. Subjects A total of 93 patients diagnosed with DTC of which 67 with papillary and 26 with follicular histology. Measurements Analysis of immunohistochemical expression of somatostatin receptor ( sst ) subtypes 1–5, glucose transporter‐1 ( GLUT ‐1), receptor tyrosine kinase c‐ KIT , oestrogen and progesterone receptors, and proliferation marker K i‐67 and correlation with the patients’ clinical outcome. Results DTC showed immunohistochemical expression of GLUT ‐1, C ‐ KIT and progesterone receptor in a high percentage of cases (range: 57–80%). In contrast, the oestrogen receptor as well as the sst subtypes 1–5 was less frequently detected (range: 15–29%). Mean staining of the proliferation marker K i‐67 was 6% positive cells (range 0–20%). K i‐67 expression was significantly associated with tumour staging (ρ = 0·2076, P = 0·0459), whereas the other histopathological markers were not associated with gender, age, tumour entity, or tumour classification. Tumour staging and expression of K i‐67, oestrogen receptor and sst2 , but of none of the other histopathological factors, independently predicted the clinical outcome 5 years after definitive treatment ( P < 0·0001, P < 0·0001, P = 0·0004 and P = 0·0206, respectively). Conclusions In patients with DTC , K i‐67 expression associates with tumour staging and clinical outcome.